Arsenic Trioxide Suppresses Growth of BCR-ABL1 Positive Cells with "Gatekeeper" or Compound Mutation

被引：0
|
作者：
Mian, Afsar Ali [1 ]
Raees, Hadiqa [1 ]
Ahmad, Sujjawal [1 ]
Ottmann, Oliver [2 ]
Lalani, El-Nasir M. A. [1 ]
机构：
[1] Aga Khan Univ, Ctr Regenerat Med & Stem Cell Res, Karachi, Pakistan
[2] Cardiff Univ, Sch Med, Div Canc & Genet, Dept Haematol, Cardiff, Wales
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-154511
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4346
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Bcr-Abl1 V304D mutation in CML: Friend or foe?
    Pricl, S.
    Laurini, E.
    Fermeglia, M.
    Dal Col, V.
    Storici, P.
    Giabbai, B.
    Semrau, M.
    De March, M.
    Donato, N. J.
    Quintas-Cardama, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S43 - S43
  • [22] Mechanism by which Arsenic Trioxide downregulates Bcr-Abl levels and potentiates Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells.
    Nimmanapalli, R
    Bali, P
    O'Bryan, E
    Kuhn, D
    Bhalla, K
    BLOOD, 2001, 98 (11) : 618A - 618A
  • [23] Mechanism by which arsenic trioxide downregulates Bcr-Abl levels and potentiates Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells.
    Nimmanapalli, R
    Bali, P
    O'Bryan, E
    Kuhn, D
    Valkov, N
    Sullivan, D
    Bhalla, KN
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3771S - 3771S
  • [24] Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
    Braun, Thorsten
    Berrou, Jeannig
    Prudent, Renaud
    Djamai, Hanane
    Dupont, Melanie
    Kaci, Anna
    Adiceam, Emilie
    Paublant, Fabrice
    Baruchel, Andre
    Ghysdael, Jacques
    Gardin, Claude
    Dombret, Herve
    BLOOD, 2018, 132
  • [25] Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib
    E A Lasater
    E S Massi
    A Stecula
    J Politi
    S K Tan
    C C Smith
    M Gunthorpe
    J P Holmes
    F Chehab
    A Sali
    N P Shah
    Leukemia, 2016, 30 : 1405 - 1409
  • [26] NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature
    Catalano, Gianfranco
    Niscola, Pasquale
    Banella, Cristina
    Diverio, Daniela
    Trawinska, Malgorzata Monika
    Fratoni, Stefano
    Iazzoni, Rita
    De Fabritiis, Paolo
    Abruzzese, Elisabetta
    Noguera, Nelida Ines
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2020, 12
  • [27] Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
    Maletzke, Saskia
    Salimi, Azam
    Vieri, Margherita
    Schroeder, Kema Marlen
    Schemionek, Mirle
    Masouleh, Behzad Kharabi
    Brummendorf, Tim H.
    Koschmieder, Steffen
    Appelmann, Iris
    PLOS ONE, 2022, 17 (10):
  • [28] Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling
    Balducci, Estelle
    Sanekli, Safa
    Hugues, Patricia
    Soubeyrand, Mathis
    Borie, Claire
    Fund, Xavier
    Desterke, Christophe
    Aumont, Cedric
    Faivre, Jamila
    Bennaceur-Griscelli, Annelise
    Turhan, Ali G.
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 209 - 212
  • [29] Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1
    Amparo Pimentel-Villar, M.
    Morales-Camacho, Rosario M.
    Teresa Vargas, M.
    Jimenez-Jambrina, Margarita
    Martin-Chacon, Eusebio
    Prats-Martin, Concepcion
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (01) : 7 - 7
  • [30] BCR-ABL1 expression in multiple myeloma cells: A case of mistaken identity?
    MacLeod, Roderick A. F.
    Nagel, Stefan
    Dirks, Wilhelm
    Drexler, Hans G.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (04) : E270 - E271
12345